Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

Background Ixekizumab (IXE) is an interleukin (IL)-17A antagonist approved for the treatment of adults with moderate-to-severe psoriasis. Objective The objective of this study was to determine if the immune response to tetanus and pneumococcal vaccines in healthy subjects administered IXE was noninf...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2017-12, Vol.31 (6), p.545-554
Hauptverfasser:	Gomez, Elisa V., Bishop, Jessie L., Jackson, Kimberley, Muram, Talia M., Phillips, Diane
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Antibodies Biological products Biomedical and Life Sciences Biomedicine Cancer Research Chronic illnesses Cytokines Disease Guillain-Barre syndrome Immune response (humoral) Immune system Immunoglobulins Influenza Molecular Medicine Monoclonal antibodies NCT NCT02543918 Original Original Research Article Pharmacokinetics Pharmacotherapy Psoriasis Rheumatoid arthritis Serotypes Studies Tetanus Tumor necrosis factor-TNF Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!